Microrna-675 Inhibits Cell Proliferation And Invasion In Melanoma By Directly Targeting Metadherin

Melanoma is derived from melanocytes and accounts for similar to 80% of skin cancer-associated fatalities worldwide. The dysregulation of microRNAs (miRNAs/miRs) is involved in the development and progression of melanoma. Therefore, miRNAs may be novel diagnostic or prognostic biomarkers and promising therapeutic targets in the treatment of patients with melanoma. miR-675 is differentially expressed in several types of human cancer and has important roles in the pathogenesis of several diseases. However, the expression levels and the biological roles of miR-675 in melanoma remain unclear. Therefore, the present study aimed to assess the expression of miR-675 in melanoma, explore the effects of miR-675 on melanoma cells and investigate the underlying molecular mechanisms that may be involved in the actions of miR-675. The present study indicated that miR-675 expression was downregulated in melanoma tissues and cell lines. Functional assays demonstrated that the upregulation of miR-675 impaired cell proliferation and invasion in melanoma. Bioinformatics analysis, luciferase reporter assay, reverse transcription-quantitative polymerase chain reaction and western blot analysis demonstrated that metadherin (MTDH) was a direct target of miR-675 in melanoma. The MTDH levels were upregulated in melanoma tissues and inversely correlated with the miR-675 expression. Furthermore, restored MTDH expression rescued the inhibition effects in melanoma cells caused by miR-675 overexpression. Thus, miR-675 may be a potential therapeutic target for melanoma.